Steady-state PK of omapatrilat in healthy subjects.

被引：8
|
作者：
Delaney, CL [1 ]
Jemal, M [1 ]
Beierle, FA [1 ]
Ferreira, IM [1 ]
Davis, KD [1 ]
Meier, A [1 ]
Ford, NF [1 ]
Uderman, HD [1 ]
Liao, W [1 ]
机构：
[1] Bristol Myers Squibb Pharmaceut Res Inst, Princeton, NJ 08543 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 1999年 / 65卷 / 02期
关键词：
D O I：
10.1016/S0009-9236(99)80066-6
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
PI66
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [31] Evaluation of the effect of duloxetine on the pharmacodynamics and pharmacokinetics of warfarin at steady-state in healthy subjects
    Chappell, J.
    He, J.
    Knadler, M. P.
    Lee, D.
    Mitchell, M.
    Lobo, F.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1123 - 1123
  • [32] Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects
    Ferron, GM
    Patat, A
    Parks, V
    Rolan, P
    Troy, SM
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 56 (01) : 39 - 45
  • [33] Single and multiple dose pharmacokinetics (PK) of rofecoxib (R) in healthy subjects.
    Porras, A
    Ko, A
    Larson, P
    Agrawal, N
    Woolf, E
    Ebel, D
    Lasseter, K
    Gertz, B
    Schwartz, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 137 - 137
  • [34] THE EFFECT OF EVEROLIMUS (EVE) ON THE PHARMACOKINETICS (PK) OF MIDAZOLAM (MID) IN HEALTHY SUBJECTS.
    Urva, S.
    Bouillaud, E.
    Delaney, R.
    Jappe, A.
    Cheung, W.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S128 - S128
  • [35] PK/PD MODELING OF SUNITINIB AFTER ORAL ADMINISTRATION IN HEALTHY SUBJECTS.
    Di Gion, P.
    Lindauer, A.
    Kanefendt, F.
    Krambeer, C.
    Rodamer, M.
    Kinzig, M.
    Soergel, F.
    Jaehde, U.
    Fuhr, U.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 : S86 - S86
  • [36] Evaluation of the potential for steady-state pharmacokinetic interaction between vildagliptin and simvastatin in healthy subjects
    Ayalasomayajula, Surya P.
    Dole, Kiran
    He, Yan-Ling
    Ligueros-Saylan, Monica
    Wang, Yibin
    Campestrini, Joelle
    Humbert, Henri
    Sunkara, Gangadhar
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 2913 - 2920
  • [37] Lack of Effect of the Novel Antibiotic Iclaprim on the Steady-State Pharmacokinetics of Digoxin in Healthy Subjects
    Leggewie, Stefan
    Cap, Meike
    Stengele, Eberhard
    Furdas, Silviya
    Hadvary, Paul
    Islam, Khalid
    Zeman, Paul
    Trenk, Dietmar
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (06) : 514 - 515
  • [38] Development and evaluation of a population pharmacokinetic (PK) model for darbepoetin alfa in healthy subjects.
    Kuebler, P
    Lu, J
    Xu, L
    Holmgren, E
    Hambleton, J
    Spyker, D
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (02) : P76 - P76
  • [39] Population pharmacokinetic (PK) modeling of microencapsulated octreotide acetate (MOA) in healthy subjects.
    Zhou, H
    Chen, TL
    Miller, T
    Marino, M
    Lau, H
    McLeod, J
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 190 - 190
  • [40] STEADY-STATE PHARMACOKINETICS (PK) OF AMINOGUANIDINE (AG) IN HEMODIALYSIS (HD)
    HALSTENSON, CE
    FOOTE, EF
    GILES, PJ
    KEANE, WF
    LOOK, ZM
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 53 (02) : 236 - 236
12345